Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.13
(-4.05%)
SEK 2.13
(-4.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.71 Million SEK | -156.37% |
| 2022 | -2.23 Million SEK | 73.49% |
| 2021 | -8.41 Million SEK | -962.67% |
| 2020 | 975 Thousand SEK | 106.68% |
| 2019 | -14.6 Million SEK | 1.85% |
| 2018 | -14.88 Million SEK | -582.31% |
| 2017 | 3.08 Million SEK | 1211.59% |
| 2016 | -277.55 Thousand SEK | -3183.91% |
| 2015 | 9000.00 SEK | -98.5% |
| 2014 | 599.95 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -17 Million SEK | -349.23% |
| 2024 Q1 | -3.78 Million SEK | 33.78% |
| 2023 FY | -5.71 Million SEK | -156.37% |
| 2023 Q3 | -6.27 Million SEK | -1642.51% |
| 2023 Q4 | -5.71 Million SEK | 8.94% |
| 2023 Q2 | 407 Thousand SEK | 135.09% |
| 2023 Q1 | -1.16 Million SEK | 47.98% |
| 2022 FY | -2.23 Million SEK | 73.49% |
| 2022 Q4 | -2.23 Million SEK | -49.06% |
| 2022 Q3 | -1.49 Million SEK | 88.56% |
| 2022 Q2 | -13.07 Million SEK | -279.45% |
| 2022 Q1 | -3.44 Million SEK | 59.04% |
| 2021 Q2 | 2.73 Million SEK | 169.25% |
| 2021 Q1 | -3.94 Million SEK | -504.62% |
| 2021 Q4 | -8.41 Million SEK | -2618.26% |
| 2021 Q3 | 334 Thousand SEK | -87.77% |
| 2021 FY | -8.41 Million SEK | -962.67% |
| 2020 Q1 | -3.87 Million SEK | 73.5% |
| 2020 Q4 | 975 Thousand SEK | -50.41% |
| 2020 Q3 | 1.96 Million SEK | 208.8% |
| 2020 Q2 | -1.8 Million SEK | 53.32% |
| 2020 FY | 975 Thousand SEK | 106.68% |
| 2019 Q4 | -14.6 Million SEK | -83.87% |
| 2019 Q3 | -7.94 Million SEK | -295.76% |
| 2019 Q2 | -2 Million SEK | 29.68% |
| 2019 Q1 | -2.85 Million SEK | 80.82% |
| 2019 FY | -14.6 Million SEK | 1.85% |
| 2018 Q3 | 1.78 Million SEK | 296.26% |
| 2018 Q2 | -909 Thousand SEK | -109.44% |
| 2018 FY | -14.88 Million SEK | -582.31% |
| 2018 Q4 | -14.88 Million SEK | -934.1% |
| 2018 Q1 | 9.62 Million SEK | 211.97% |
| 2017 Q4 | 3.08 Million SEK | 86.76% |
| 2017 Q2 | -1.15 Million SEK | -163.96% |
| 2017 Q1 | 1.8 Million SEK | 751.77% |
| 2017 FY | 3.08 Million SEK | 1211.59% |
| 2017 Q3 | 1.65 Million SEK | 242.78% |
| 2016 FY | -277.55 Thousand SEK | -3183.91% |
| 2016 Q2 | -6.78 Million SEK | -1359.18% |
| 2016 Q4 | -277.55 Thousand SEK | 90.57% |
| 2016 Q1 | 539 Thousand SEK | 5888.89% |
| 2016 Q3 | -2.94 Million SEK | 56.65% |
| 2015 Q4 | 9000.00 SEK | 0.0% |
| 2015 Q1 | 45.00 SEK | 0.0% |
| 2015 FY | 9000.00 SEK | -98.5% |
| 2014 FY | 599.95 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 70.292% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 80.354% |
| BioGaia AB (publ) | -1.53 Billion SEK | 99.628% |
| Enzymatica AB (publ) | 17.73 Million SEK | 132.232% |
| Gabather AB (publ) | -1.11 Million SEK | -412.735% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 132.327% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 89.758% |
| Nanexa AB (publ) | -61.13 Million SEK | 90.649% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 62.641% |
| ODI Pharma AB | -2.63 Million SEK | -116.725% |
| Orexo AB (publ) | 302.8 Million SEK | 101.888% |
| Probi AB (publ) | -275.85 Million SEK | 97.928% |
| Swedencare AB (publ) | 1.42 Billion SEK | 100.402% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.029% |
| Toleranzia AB | -17.45 Million SEK | 67.245% |
| Vivesto AB | -1.29 Million SEK | -340.108% |